Document is current

Article History

Received: 25 March 2025

Accepted: 18 May 2025

First Online: 10 June 2025

Declarations

:

: The authors declare no direct competing interests related to this study. However, as this study utilizes data from the MONSTAR-SCREEN-3 trial, potential indirect competing interests may exist through that relationship. Here is that list: Hashimoto T. reports honoraria from CytoGen and Takata Pharmaceutical. Nakamura Y. reports personal fees from Guardant Health Pte, Ltd., Natera, Inc., Roche, Ltd., Premo Partners, Inc., Takeda Pharmaceutical, Exact Sciences Corporation, Gilead Sciences, Inc., MSD, Eisai Co., Ltd., Zeria Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Becton, Dickinson and Company, and Guardant Health Japan Corp.; grants and personal fees from Seagen, Inc., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; as well as grants from Genomedia Inc., Guardant Health AMEA, Inc., Guardant Health, Inc., Tempus Labs, Inc., and Roche Diagnostics K.K. outside the submitted work. Fujisawa T. reports personal fees from Amelieff and AstraZeneca outside the submitted work. Imai M. reports personal fees from Caris Life Sciences, Guardant Health, Inc., and Sumitomo Corp outside the submitted work. Misumi T. reports honoraria from Chugai and AstraZeneca. Bando H. reports personal fees from Ono Pharmaceutical, Taiho Pharmaceutical, and Eli Lilly Japan K. K. outside the submitted work. Yoshino T. reports personal fees from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical, Merck Biopharma Co. Ltd., Bayer Yakuhin, Ono Pharmaceutical, MSD, and Sumitomo Corp, as well as grants from Amgen, Chugai Pharmaceutical, Daiichi Sankyo, Eisai Co. Ltd., FALCO Biosystems, Genomedia, Molecular Health, MSD, Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical, Pfizer, Roche Diagnostics, Sanofi, Sysmex, and Taiho Pharmaceutical outside the submitted work. The other authors have no competing interests to declare.

: This study was approved by the Institutional Review Board of the National Cancer Center Hospital East (approval number: 2024-111). All study procedures will be conducted in accordance with the Declaration of Helsinki and Japan's Ethical Guidelines for Medical and Health Research Involving Human Subjects.

: Written informed consent will be obtained from all the participants before enrollment in the study. The informed consent process includes detailed explanation of the study procedures, data collection methods, and potential risks and benefits.

: All participants have provided written informed consent for publication of the research results in academic journals and presentation at medical conferences. The data will be presented in a manner that ensures no individual participant can be identified.